oOur Approach

Quantum AI

Unlike most other computational approaches, Quantum AI leads with quantum mechanics to model and describe drug-target interactions.

Quantum AI is also enhanced by proprietary AI, machine learning, big data and cheminformatics algorithms.

Our proprietary technology platform accelerates the identification of higher quality, chemotypically diverse, preclinical assets for “hard to drug” diseases with high unmet need – paving the way for better clinical outcomes.

oFast, cost-effective and diverse

A FAR better discovery process

We collapse the hit identification and hit-to-lead process, saving considerable time and expense in delivering higher quality preclinical leads.

We have achieved a hit rate as high as 30-50% for diverse target types.